Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.4
4.2
Journals
Membranes
Special Issues
Drug Delivery Systems Based on Extracellular Vesicles
share announcement

Drug Delivery Systems Based on Extracellular Vesicles

A special issue of Membranes (ISSN 2077-0375). This special issue belongs to the section "Biological Membrane Functions".

Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 7776

Special Issue Editors

Dr. Yasunari Matsuzaka

E-Mail Website
Guest Editor
Division of Molecular and Medical Genetics, Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan
Interests: extracellular vesicles; vaccine; cancer; mRNA; microRNAs; immune responses; T cells; dendritic cells; major histocompatibility complex (MHC); deep learning; virus
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Yoshihiro Uesawa

E-Mail Website
Guest Editor
Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo 204-858, Japan
Interests: computational toxicology; pharmacokinetics; pharmacovigilance
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Recently, emerging evidence that extracellular vesicles (EVs), including exosomes, play a critical role as new drug delivery systems and biomarkers has attracted attention. Through intercellular communications, EVs can mediate cargo transport, such as proteins, lipids, and nucleic acids, and particularly non-coding RNAs, leading to functional modulations of key molecules in both physiological and pathological conditions, such as proliferation, differentiation, apoptosis, inflammation, regeneration, or immune tolerance.

This Special Issue aims to highlight the latest research on the role, purification, biogenesis, and structure of EVs in physiological or pathological areas. The topics that we intend to cover include (but are not limited to) the following:

  • Intercellular communications by EVs and miRNAs;
  • Drug delivery systems through EVs;
  • Purification, biogenesis, and structure of EVs.

We welcome both research and review articles and look forward to receiving your contributions. 

Dr. Yasunari Matsuzaka
Prof. Dr. Yoshihiro Uesawa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Membranes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • extracellular vesicles(EVs)
  • microRNAs
  • intercellular communication
  • biomarkers
  • purification and biogenesis of EVs
  • inflammation or immune tolerance

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 2519 KiB  
Article
Ameliorative Effects of Camel Milk and Its Exosomes on Diabetic Nephropathy in Rats
by Amira M. Shaban, Mai Raslan, Safa H. Qahl, Khaled Elsayed, Mohamed Sayed Abdelhameed, Atif Abdulwahab A. Oyouni, Osama M. Al-Amer, Ola Hammouda and Mohammed A. El-Magd
Membranes 2022, 12(11), 1060; https://doi.org/10.3390/membranes12111060 - 28 Oct 2022
Cited by 7 | Viewed by 2146
Abstract
Contradictory results were obtained regarding the effects of extracellular vesicles such as exosomes (EXOs) on diabetes and diabetic nephropathy (DN). Some studies showed that EXOs, including milk EXOs, were involved in the pathogenesis of DN, whereas other studies revealed ameliorative effects. Compared to [...] Read more.
Contradictory results were obtained regarding the effects of extracellular vesicles such as exosomes (EXOs) on diabetes and diabetic nephropathy (DN). Some studies showed that EXOs, including milk EXOs, were involved in the pathogenesis of DN, whereas other studies revealed ameliorative effects. Compared to other animals, camel milk had unique components that lower blood glucose levels. However, little is known regarding the effect of camel milk and its EXOs on DN. Thus, the present study was conducted to evaluate this effect on a rat model of DN induced by streptozotocin. Treatment with camel milk and/or its EXOs ameliorated DN as evidenced by (1) reduced levels of kidney function parameters (urea, creatinine, retinol-binding protein (RBP), and urinary proteins), (2) restored redox balance (decreased lipid peroxide malondialdehyde (MDA) and increased the activity of antioxidants enzymes superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx)), (3) downregulated expression of DN-related genes (transforming growth factor-beta 1 (TGFβ1), intercellular adhesion molecules 1 (ICAM1), and transformation specific 1 (ETS1), integrin subunit beta 2 (ITGβ2), tissue inhibitors of matrix metalloproteinase 2 (TIMP2), and kidney injury molecule-1 (KIM1)), and (4) decreased renal damage histological score. These results concluded that the treatment with camel milk and/or its EXOs could ameliorate DN with a better effect for the combined therapy. Full article
(This article belongs to the Special Issue Drug Delivery Systems Based on Extracellular Vesicles)
►▼ Show Figures

Figure 1

Review

Jump to: Research

30 pages, 11423 KiB  
Review
Potential of Lipid-Based Nanocarriers against Two Major Barriers to Drug Delivery—Skin and Blood–Brain Barrier
by Mohammad Sameer Khan, Sradhanjali Mohapatra, Vaibhav Gupta, Ahsan Ali, Punnoth Poonkuzhi Naseef, Mohamed Saheer Kurunian, Abdulkhaliq Ali F. Alshadidi, Md Shamsher Alam, Mohd. Aamir Mirza and Zeenat Iqbal
Membranes 2023, 13(3), 343; https://doi.org/10.3390/membranes13030343 - 16 Mar 2023
Cited by 3 | Viewed by 3064
Abstract
Over the past few years, pharmaceutical and biomedical areas have made the most astounding accomplishments in the field of medicine, diagnostics and drug delivery. Nanotechnology-based tools have played a major role in this. The implementation of this multifaceted nanotechnology concept encourages the advancement [...] Read more.
Over the past few years, pharmaceutical and biomedical areas have made the most astounding accomplishments in the field of medicine, diagnostics and drug delivery. Nanotechnology-based tools have played a major role in this. The implementation of this multifaceted nanotechnology concept encourages the advancement of innovative strategies and materials for improving patient compliance. The plausible usage of nanotechnology in drug delivery prompts an extension of lipid-based nanocarriers with a special reference to barriers such as the skin and blood–brain barrier (BBB) that have been discussed in the given manuscript. The limited permeability of these two intriguing biological barriers restricts the penetration of active moieties through the skin and brain, resulting in futile outcomes in several related ailments. Lipid-based nanocarriers provide a possible solution to this problem by facilitating the penetration of drugs across these obstacles, which leads to improvements in their effectiveness. A special emphasis in this review is placed on the composition, mechanism of penetration and recent applications of these carriers. It also includes recent research and the latest findings in the form of patents and clinical trials in this field. The presented data demonstrate the capability of these carriers as potential drug delivery systems across the skin (referred to as topical, dermal and transdermal delivery) as well as to the brain, which can be exploited further for the development of safe and efficacious products. Full article
(This article belongs to the Special Issue Drug Delivery Systems Based on Extracellular Vesicles)
►▼ Show Figures

Figure 1

21 pages, 1493 KiB  
Review
Advances in Purification, Modification, and Application of Extracellular Vesicles for Novel Clinical Treatments
by Yasunari Matsuzaka and Ryu Yashiro
Membranes 2022, 12(12), 1244; https://doi.org/10.3390/membranes12121244 - 08 Dec 2022
Cited by 9 | Viewed by 1985
Abstract
Extracellular vesicles (EV) are membrane vesicles surrounded by a lipid bilayer membrane and include microvesicles, apoptotic bodies, exosomes, and exomeres. Exosome-encapsulated microRNAs (miRNAs) released from cancer cells are involved in the proliferation and metastasis of tumor cells via angiogenesis. On the other hand, [...] Read more.
Extracellular vesicles (EV) are membrane vesicles surrounded by a lipid bilayer membrane and include microvesicles, apoptotic bodies, exosomes, and exomeres. Exosome-encapsulated microRNAs (miRNAs) released from cancer cells are involved in the proliferation and metastasis of tumor cells via angiogenesis. On the other hand, mesenchymal stem cell (MSC) therapy, which is being employed in regenerative medicine owing to the ability of MSCs to differentiate into various cells, is due to humoral factors, including messenger RNA (mRNA), miRNAs, proteins, and lipids, which are encapsulated in exosomes derived from transplanted cells. New treatments that advocate cell-free therapy using MSC-derived exosomes will significantly improve clinical practice. Therefore, using highly purified exosomes that perform their original functions is desirable. In this review, we summarized advances in the purification, modification, and application of EVs as novel strategies to treat some diseases. Full article
(This article belongs to the Special Issue Drug Delivery Systems Based on Extracellular Vesicles)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop